Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 03/06/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications
Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib.
Journal: Journal of the advanced practitioner in oncology
Published: January 13, 2025
A perspective on the application of macrocyclic design strategies in antitumor drugs.
Journal: Bioorganic chemistry
Published: October 23, 2024
High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
Journal: Biochemical and biophysical research communications
Published: September 24, 2024
JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: September 04, 2024
Treatment Strategies Used in Treating Myelofibrosis: State of the Art.
Journal: Hematology reports
Published: August 29, 2024
Pacritinib and concurrent azole antifungal therapy is deliverable in patients with hematologic malignancies.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: August 19, 2024
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 13, 2024
Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a-/- murine model.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 12, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
Journal: Expert opinion on pharmacotherapy
Published: July 27, 2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of Survival.
Journal: European journal of haematology
Published: June 20, 2024
Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology.
Journal: Cell communication and signaling : CCS
Published: June 19, 2024
Muti-target rationale design of novel substituted N-phenyl-2-((6-phenylpyridazin-3-yl)thio)acetamide candidates as telomerase/JAK1/STAT3/TLR4 inhibitors: In vitro and in vivo investigations.
Journal: Bioorganic chemistry
Published: June 11, 2024
Last Updated: 03/06/2025